StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — BOB Capital Markets

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)6 May 2026via Institutional / Brokerage Research

Entry₹1,659.5Inferred
Target₹1,965
Total upside +18.41% (call closed)
Stop lossNot given
Exit₹1,96531 Jul 2026, 12:07 pm
Target hit+18.41%0.00%upside left
Follow BOB Capital Markets for new calls(63% target hit, 357 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 6 active Long-term calls on EMCURESee 214 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Jul 2026
10 supporting1 neutral1 opposing
Supports the BUY call (10)

Emcure Pharmaceuticals Ltd has completed the acquisition of shares in Gennova Biopharmaceuticals Limited, indicating a strategic expansion.

BSE · Company Update·22 Jul · 1w ago

(opens in new tab)

Emcure Pharmaceuticals has received CDSCO approval to expand the use of its drug Poviztra for MASH indication, potentially increasing market reach and revenue.

BSE · Company Update·20 Jul · 1w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·20 Jul · 2w ago

Novo Nordisk's Wegovy wins India nod for fatty liver disease; Emcure to distribute

NewsCnbc-Tv18·17 Jul · 2w ago

(opens in new tab)

Emcure Pharmaceuticals Ltd's press release indicates consolidation of Gennova ownership and a sharpened focus on biologics, with Samit Mehta leading growth.

BSE · Company Update·13 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Emcure Pharmaceuticals gets CDSCO nod for MASH treatment in adults with liver fibrosis

NewsCnbc-Tv18·20 Jul · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from BOB Capital Markets

Every call and its outcome